Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
RATIONALE: Measuring the number of radiolabeled white blood cells in non-Hodgkin's lymphoma
 tumors may help doctors predict how well patients will respond to treatment, and may help the
 study of cancer in the future.

 PURPOSE: This study is measuring radiolabeled white blood cells in patients with
 non-Hodgkin's lymphoma.
OBJECTIVES:

 -  Determine the number of indium In 111-labeled peripheral blood mononuclear cells (PBMCs)
 and indium In 111-labeled polymorphonuclear leukocytes (PMNLs) trafficking into lymphoma
 tumors prior to therapy in patients with non-Hodgkin's lymphoma.

 -  Compare the number of PBMC and PMNL trafficking prior to vs after therapy in these
 patients.

 -  Compare, preliminarily, the number of in vivo baseline (i.e., pre-therapy) trafficking
 of PBMCs vs PMNLs in these patients.

 -  Gather important data regarding the inter- and intra-patient variability of effector
 cell trafficking into these tumors.

 -  Assess the relationship between response at 8-12 weeks and the magnitude of baseline
 effector cell trafficking or the magnitude of post-rituximab effector cell trafficking
 in these patients.

 OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups.

 -  Group I: Patients receive autologous indium In 111 (^111In)-labeled peripheral blood
 mononuclear cells on day 0.

 -  Group II: Patients receive autologous ^111In-labeled polymorphonuclear leukocytes on day
 0.

 In both groups, patients undergo blood collection on day 0. Patients then undergo full-body
 single-photon emission-computed tomography (SPECT) scan 4 hours after cell infusion and on
 day 2. The labeling and imaging process may be repeated after at least 1 course of anticancer
 treatment.

 Cellular uptake is measured by reader/visual interpretation, a semiquantitative grading
 system, and tumor-to-background uptake ratios.

 PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
DISEASE CHARACTERISTICS:

 -  Histologically or cytologically confirmed non-Hodgkin's lymphoma

 -  Indolent or aggressive disease

 -  Planning to receive a new regimen or starting a regimen of cancer therapy

 -  At least one tumor lesion measurable in two dimensions as ≥ 1.5 cm by CT scan

 PATIENT CHARACTERISTICS:

 -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

 -  Life expectancy ≥ 3 months

 -  No concurrent medical complications that would preclude study compliance

 -  Not pregnant or nursing

 PRIOR CONCURRENT THERAPY:

 -  At least 3 weeks since prior chemotherapy (except for nonmyelosuppressive treatments)

 -  At least 3 weeks since prior radiation therapy

 -  Concurrent rituximab allowed